Haematopoietic stem cell mobilisation followed by high‐dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma
Samir Asher(University College Hospital), Neil Rabin(University College London), Jonathan Sive(University College London Hospitals NHS Foundation Trust), Ke Xu(University College London Hospitals NHS Foundation Trust), L. Lee(University College Hospital), Sara Trompeter(NHS Blood and Transplant), Brendan Wisniowski(The Royal Free Hospital), Fiona Newrick(University College Hospital), Charalampia Kyriakou(The Royal Free Hospital), Annabel McMillan(University College London Hospitals NHS Foundation Trust), Matthew Streetly(King's College - North Carolina), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Rakhee Shah(Association for Young People’s Health), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Rachel Kesse-Adu(Guy's and St Thomas' NHS Foundation Trust), S. Mahmood(University College Hospital), J. Horder(University College Hospital), George Nesr(University College Hospital), Stuart J. Ings(University College Hospital), X. Papanikalaou(University College Hospital)
Cited by 1
Related Papers
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
|Blood|2018|421